Bo-Heng Zhang
Overview
Explore the profile of Bo-Heng Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
2571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang D, Sun B, Wu J, Wang Z, Zheng S, Sun G, et al.
Curr Oncol
. 2025 Feb;
32(2).
PMID: 39996856
: Cystatin B (CSTB) has been demonstrated to play a significant role in the pathogenesis of a number of diseases, including the evolution and progression of multiple cancers. Nevertheless, the...
2.
Sun B, Zhang D, Gan W, Wu J, Wang Z, Sun G, et al.
J Cancer Res Clin Oncol
. 2024 Jul;
150(7):348.
PMID: 39002018
Background & Aims: Patients with intrahepatic cholangiocarcinoma (iCCA) respond poorly to immune checkpoint blockades (ICBs). In this study, we aimed to dissect the potential mechanisms underlying poor response to ICBs...
3.
Zheng S, Wu J, Wu W, Hu J, Zhang D, Huang C, et al.
Hepatol Int
. 2024 May;
18(5):1499-1515.
PMID: 38769286
Background: Chromobox Homolog 1 (CBX1) plays a crucial role in the pathogenesis of numerous diseases, including the evolution and advancement of diverse cancers. The role of CBX1 in pan-cancer and...
4.
Xu B, Dong S, Bai X, Song T, Zhang B, Zhou L, et al.
Liver Cancer
. 2023 Aug;
12(3):262-276.
PMID: 37601982
Introduction: Lenvatinib plus an anti-PD-1 antibody has shown promising antitumor effects in patients with advanced hepatocellular carcinoma (HCC), but with clinical benefit limited to a subset of patients. We developed...
5.
Zheng S, Wu Y, Zhang B, Huang C, Xue T
Front Mol Biosci
. 2023 Mar;
10:1118377.
PMID: 36959981
Myeloid cells are physiologically related to innate immunity and inflammation. Tumor-associated myeloid cells gained increasing interest because of their critical roles in tumor progression and anticancer immune responses in human...
6.
Jing C, Fu Y, Zhou C, Zhang M, Yi Y, Huang J, et al.
Oncogene
. 2021 Mar;
40(16):2910-2922.
PMID: 33742120
Intrahepatic cholangiocarcinoma (ICC) is a highly fatal malignancy characterized by a vast amount of intra-tumoral fibroblasts. These fibroblasts are potentially implicated in maintaining the high aggressiveness of ICC, whereas its...
7.
Wang J, Wang Q, Wang X, Jin X, Zhang B, Chen S, et al.
Chronic Dis Transl Med
. 2020 Jun;
6(2):134-139.
PMID: 32596650
Objective: Clinical practice guidelines can improve healthcare processes and patient outcomes; however, the quality of these guidelines varies greatly in China. The aim of this study was to construct a...
8.
Chen R, Gan Y, Ge N, Chen Y, Ma M, Zhang B, et al.
J Cancer
. 2019 Nov;
10(26):6535-6542.
PMID: 31777583
: The prognosis of patients with intermediate-stage hepatocellular carcinoma (HCC) treated by conventional TACE (cTACE) is greatly heterogeneous. This study aimed to develop a new survival prediction model to help...
9.
Jing C, Fu Y, Yi Y, Zhang M, Zheng S, Huang J, et al.
J Immunother Cancer
. 2019 Mar;
7(1):77.
PMID: 30885276
Background: Intrahepatic cholangiocarcinoma (ICC) is a highly mortal malignancy with limited therapeutic options. Immunotherapies targeting PD-1/PD-L1 pathway represent a promising treatment for ICC. However, PD-L1 expression and microsatellite instability are...
10.
Zhang M, Gan W, Jing C, Zheng S, Yi Y, Zhang J, et al.
J Cancer
. 2019 Mar;
10(5):1313-1324.
PMID: 30854141
Oct4 and Nanog are reported to promote tumor progression in several cancers, but the effect on intrahepatic cholangiocarcinoma (ICC) is unknown. The aim of our present study was to explore...